IDEXX Laboratories, Inc. $IDXX Shares Acquired by Swedbank AB

Swedbank AB lifted its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 5.9% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 37,832 shares of the company’s stock after acquiring an additional 2,107 shares during the quarter. Swedbank AB’s holdings in IDEXX Laboratories were worth $24,170,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in IDXX. STF Management LP raised its position in shares of IDEXX Laboratories by 1.3% in the second quarter. STF Management LP now owns 1,240 shares of the company’s stock worth $665,000 after acquiring an additional 16 shares during the period. Clearstead Trust LLC grew its holdings in IDEXX Laboratories by 1.1% in the second quarter. Clearstead Trust LLC now owns 1,515 shares of the company’s stock valued at $813,000 after purchasing an additional 16 shares during the period. Stratos Wealth Partners LTD. increased its position in shares of IDEXX Laboratories by 1.7% in the second quarter. Stratos Wealth Partners LTD. now owns 1,051 shares of the company’s stock valued at $564,000 after buying an additional 18 shares in the last quarter. Red Spruce Capital LLC raised its stake in shares of IDEXX Laboratories by 1.1% during the 2nd quarter. Red Spruce Capital LLC now owns 1,701 shares of the company’s stock worth $912,000 after buying an additional 19 shares during the period. Finally, Huntington National Bank raised its stake in shares of IDEXX Laboratories by 0.5% during the 2nd quarter. Huntington National Bank now owns 3,651 shares of the company’s stock worth $1,958,000 after buying an additional 19 shares during the period. Institutional investors and hedge funds own 87.84% of the company’s stock.

Insider Activity

In related news, EVP Nimrata Hunt sold 9,425 shares of the stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $703.34, for a total value of $6,628,979.50. Following the completion of the sale, the executive vice president owned 21,149 shares of the company’s stock, valued at approximately $14,874,937.66. This trade represents a 30.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.98% of the stock is owned by company insiders.

Analysts Set New Price Targets

IDXX has been the topic of a number of research analyst reports. Jefferies Financial Group reissued a “buy” rating and issued a $830.00 price target on shares of IDEXX Laboratories in a research note on Tuesday, November 4th. BTIG Research lifted their target price on shares of IDEXX Laboratories from $785.00 to $830.00 and gave the company a “buy” rating in a research report on Tuesday, November 4th. Stifel Nicolaus set a $775.00 price target on shares of IDEXX Laboratories in a research report on Monday, November 3rd. Barclays began coverage on shares of IDEXX Laboratories in a research note on Monday, December 8th. They issued an “overweight” rating and a $850.00 price target on the stock. Finally, UBS Group boosted their price objective on IDEXX Laboratories from $710.00 to $750.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 4th. Seven equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $763.50.

IDEXX Laboratories Price Performance

Shares of NASDAQ IDXX opened at $688.48 on Friday. The firm has a 50-day simple moving average of $695.70 and a 200-day simple moving average of $631.35. The company has a quick ratio of 0.87, a current ratio of 1.18 and a debt-to-equity ratio of 0.24. The stock has a market capitalization of $54.98 billion, a price-to-earnings ratio of 54.60, a price-to-earnings-growth ratio of 4.11 and a beta of 1.67. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Monday, November 3rd. The company reported $3.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.14 by $0.08. The company had revenue of $1.11 billion during the quarter, compared to analysts’ expectations of $1.07 billion. IDEXX Laboratories had a net margin of 24.65% and a return on equity of 67.78%. IDEXX Laboratories’s revenue was up 13.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.80 EPS. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. On average, equities analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.